tradingkey.logo

Cytek Biosciences Inc

CTKB
查看详细走势图
5.100USD
+0.030+0.59%
收盘 12/26, 16:00美东报价延迟15分钟
652.11M总市值
亏损市盈率 TTM

Cytek Biosciences Inc

5.100
+0.030+0.59%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+0.59%

5天

+3.03%

1月

-8.93%

6月

+43.66%

今年开始到现在

-21.42%

1年

-20.19%

查看详细走势图

TradingKey Cytek Biosciences Inc股票评分

单位: USD 更新时间: 2025-12-26

操作建议

Cytek Biosciences Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名59/207位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价5.75。中期看,股价处于上升通道。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Cytek Biosciences Inc评分

相关信息

行业排名
59 / 207
全市场排名
168 / 4563
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 5 位分析师
买入
评级
5.750
目标均价
+18.31%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Cytek Biosciences Inc亮点

亮点风险
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
业绩高增长
公司营业收入稳步增长,连续3年增长22.20%
估值高估
公司最新PE估值-49.67,处于3年历史高位
机构减仓
最新机构持股80.93M股,环比减少0.00%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓,最新持仓市值438.00

Cytek Biosciences Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Cytek Biosciences Inc简介

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
公司代码CTKB
公司Cytek Biosciences Inc
CEOJiang (Wenbin)
网址https://cytekbio.com

常见问题

Cytek Biosciences Inc(CTKB)的当前股价是多少?

Cytek Biosciences Inc(CTKB)的当前股价是 5.100。

Cytek Biosciences Inc的股票代码是什么?

Cytek Biosciences Inc的股票代码是CTKB。

Cytek Biosciences Inc股票的52周最高点是多少?

Cytek Biosciences Inc股票的52周最高点是7.300。

Cytek Biosciences Inc股票的52周最低点是多少?

Cytek Biosciences Inc股票的52周最低点是2.370。

Cytek Biosciences Inc的市值是多少?

Cytek Biosciences Inc的市值是652.11M。

Cytek Biosciences Inc的净利润是多少?

Cytek Biosciences Inc的净利润为-6.02M。

现在Cytek Biosciences Inc(CTKB)的股票是买入、持有还是卖出?

根据分析师评级,Cytek Biosciences Inc(CTKB)的总体评级为买入,目标价格为5.750。

Cytek Biosciences Inc(CTKB)股票的每股收益(EPS TTM)是多少

Cytek Biosciences Inc(CTKB)股票的每股收益(EPS TTM)是-0.103。
KeyAI